Adial Pharmaceuticals/$ADIL
1D1W1MYTD1Y5YMAX
Capital at risk
About Adial Pharmaceuticals
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.
- Ticker
- $ADIL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 5
- Headquarters
- Glen Allen, United States
- Website
- www.adial.com
ADIL Metrics
BasicAdvanced
$13M
-
-$22.01
1.39
-
Price and volume
Market cap
$13M
Beta
1.39
52-week high
$7.20
52-week low
$1.31
Average daily volume
63K
Financial strength
Current ratio
5.633
Quick ratio
5.607
Interest coverage (TTM)
-5.56%
Profitability
EBITDA (TTM)
-11.491
Management effectiveness
Return on assets (TTM)
-40.02%
Return on equity (TTM)
-2,011.64%
Valuation
Price to book
-0.33
Price to tangible book (TTM)
-0.33
Price to free cash flow (TTM)
-1.146
Free cash flow yield (TTM)
-87.23%
Free cash flow per share (TTM)
-4.24
Growth
Earnings per share change (TTM)
-23.28%
3-year earnings per share growth (CAGR)
-50.36%
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.